Vanda Pharmaceuticals Inc. (NASDAQ:VNDA – Get Free Report) has been assigned an average rating of “Moderate Buy” from the eight research firms that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $13.70.
VNDA has been the subject of several research analyst reports. B. Riley Financial reaffirmed a “buy” rating and issued a $12.00 price objective (down from $17.00) on shares of Vanda Pharmaceuticals in a report on Monday, August 10th. HC Wainwright lowered their target price on Vanda Pharmaceuticals from $21.00 to $20.00 and set a “buy” rating on the stock in a report on Monday, August 10th. Wall Street Zen downgraded Vanda Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 9th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research note on Friday, July 17th.
Read Our Latest Research Report on Vanda Pharmaceuticals
Vanda Pharmaceuticals Stock Performance
Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported ($1.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.46). The company had revenue of $50.53 million for the quarter, compared to the consensus estimate of $61.92 million. Vanda Pharmaceuticals had a negative net margin of 127.41% and a negative return on equity of 49.81%. As a group, equities research analysts expect that Vanda Pharmaceuticals will post -3 earnings per share for the current year.
Institutional Investors Weigh In On Vanda Pharmaceuticals
A number of hedge funds have recently modified their holdings of VNDA. Torren Management LLC bought a new position in Vanda Pharmaceuticals in the 4th quarter worth $25,000. Hsbc Holdings PLC grew its holdings in Vanda Pharmaceuticals by 8.8% during the first quarter. Hsbc Holdings PLC now owns 38,855 shares of the biopharmaceutical company’s stock valued at $261,000 after purchasing an additional 3,144 shares during the period. Panagora Asset Management Inc. increased its position in Vanda Pharmaceuticals by 3.4% in the fourth quarter. Panagora Asset Management Inc. now owns 118,987 shares of the biopharmaceutical company’s stock worth $1,049,000 after buying an additional 3,928 shares in the last quarter. Jane Street Group LLC increased its position in Vanda Pharmaceuticals by 6.1% in the second quarter. Jane Street Group LLC now owns 79,107 shares of the biopharmaceutical company’s stock worth $373,000 after buying an additional 4,533 shares in the last quarter. Finally, Quantbot Technologies LP purchased a new stake in Vanda Pharmaceuticals in the second quarter worth about $29,000. Institutional investors own 88.14% of the company’s stock.
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.
Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.
Featured Stories
- Five stocks we like better than Vanda Pharmaceuticals
- Commodities Are Booming, But These 3 ETFs Tell Different Stories
- 3 Active ETFs Making Big Moves in August
- This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
- Birkenstock Beats the Skeptics—But Not on EPS
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
